Key result
Elevated cardiac biomarkers in pulmonary embolism showed positive predictive values for in-hospital mortality of 6 to 44% and negative predictive values for uneventful outcome above 93%.
Why the study?
Can cardiac biomarkers identify normotensive pulmonary embolism patients at high risk for adverse outcomes to justify thrombolytic therapy?
Can cardiac biomarkers identify normotensive pulmonary embolism patients at high risk for adverse outcomes to justify thrombolytic therapy?
While elevated cardiac biomarkers correlate with in-hospital mortality in pulmonary embolism, their positive predictive value is insufficient to broadly recommend thrombolytic therapy based on biomarkers alone.
Answers are grounded in this paper and cite their sources.
Insufficient PPV limits biomarker-guided thrombolysis in normotensive PE; leaves open prospective validation of integrated risk models.
PURPOSE OF REVIEW: Controversy exists about the precise role of thrombolytic therapy in normotensive patients with pulmonary embolism. To resolve this controversy two major questions must be addressed. First, can a subgroup of normotensive pulmonary embolism patients with a high risk for adverse outcomes, such as in-hospital mortality or early recurrent venous thromboembolism, be identified? Second, is there convincing evidence that the benefits of more aggressive therapy counterbalance its risks?Troponin I and T as well as brain natriuretic peptide (BNP) have recently been introduced as promising tools in the risk assessment of patients with pulmonary embolism. RECENT FINDINGS: The studies in series of patients with pulmonary embolism showed prevalences of elevated cardiac biomarkers of 16 to 84%. Positive predictive values for in-hospital mortality varied from 6 to 44%, whereas negative predictive values for uneventful outcome were above 93% in all studies. SUMMARY: Although a correlation between elevated biomarkers and in-hospital mortality in pulmonary embolism patients is present in most of the studies, the positive predictive value appears to be insufficient to extend the indication for thrombolytic therapy to all patients with elevated biomarkers. Future research is necessary to show whether combining different biomarkers with echocardiography is more useful.
No takes yet. Share an insight, caveat, or question.
Söhne et al. (2004) conducted a review in pulmonary embolism. Elevated cardiac biomarkers (Troponin I, T, BNP) was evaluated on in-hospital mortality. Elevated cardiac biomarkers in pulmonary embolism showed positive predictive values for in-hospital mortality of 6 to 44% and negative predictive values for uneventful outcome above 93%.
Synapse has enriched 10 related papers. Consider them for comparative context: